Compare Recursion Pharmaceuticals Inc (RXRX) vs Verizon Communications Inc (VZ) Price & Performance

Recursion Pharmaceuticals IncTrade

Verizon Communications IncTrade

Price performance (Past 24H)

Key statistics

Recursion Pharmaceuticals Inc vs Verizon Communications Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Verizon Communications Inc trades at $47.18 (market cap $195.40B). The key difference: Verizon Communications Inc is far larger — about 109.8× Recursion Pharmaceuticals Inc's market cap, and Verizon Communications Inc pays a 6.02% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

	RXRX	VZ
Market Cap	$1.78B	$195.40B
Sector	Health	Media
52-Week High	$6.79	$51.38
52-Week Low	$2.84	$38.40
Enterprise Value	$1.30B	$382.11B
Volume	—	22,584,735
Dividend Yield	—	6.02%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Verizon Communications Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

RXRX

Recursion Pharmaceuticals faces slow growth and cash burn despite AI drug discovery partnerships.Seeking Alpha · 1 day agoBearish View details →

Invesco's PEY ETF outperforms with a dividend-growth filter, offering higher returns and reliable income.24/7 Wall Street · 17 hours agoBullish Verizon remains a strong buy with fiber growth and $1B deal despite slight revenue dipSeeking Alpha · 2 days agoBullish Verizon cellphone service outage affects thousands in major US cities Saturday afternoonCNBC · 3 days agoBearish View details →

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

About Verizon Communications Inc

Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.